中国医疗集团：截至二零二四年十二月三十一日止之业绩公告

CHINA HEALTH GROUP INC.中國醫療集團有限公司 (Carrying on business in Hong Kong as“萬全醫療集團”)(以「萬全醫療集團」名稱在香港經營業務)(Incorporated in the Cayman Islands with limited liability)(於 開 曼 群 島 註 冊 成 立 之 有 限 公 司)(Stock Code: 08225)(股份代號: 08225) ANNUAL RESULTS ANNOUNCEMENT FOR THEYEAR ENDED 31 DECEMBER 2024 截至二零二四年十二月三十一日止之業績公告 CHARACTERISTICS OF GEM OF THE STOCK EXCHANGE OF HONG KONG LIMITED(THE “STOCK EXCHANGE”) GEM has been positioned as a market designed to accommodate small and mid-sized companies to which a higherinvestment risk may be attached than other companies listed on the Stock Exchange. Prospective investors should be awareof the potential risks of investing in such companies and should make the decision to invest only after due and carefulconsideration. Given that the companies listed on GEM are generally small and mid-sized companies, there is a risk that securities tradedon GEM may be more susceptible to high market volatility than securities traded on the Main Board and no assurance isgiven that there will be a liquid market in the securities traded on GEM. Hong Kong Exchanges and Clearing Limited and the Stock Exchange take no responsibility for the contents of this announcement,make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoeverarising from or in reliance upon the whole or any part of the contents of this announcement. This announcement for which the directors (the “Directors”) of China Health Group Inc. (the “Company” and together with itssubsidiaries, the “Group”) collectively and individually accept full responsibility, includes particulars given in compliance with theRules Governing the Listing of Securities on the GEM of the Stock Exchange (the “GEM Listing Rules”) for the purpose of givinginformation with regard to China Health Group Inc. The Directors, having made all reasonable enquires, confirm that, to the bestof their knowledge in for mufion and belief: (1) the information contained in this announcement is accurate and complete in allmaterial respects and not misleading or deceptive; (2) there are no other matters the omission of which would make any statementin this announcement herein or this announcement misleading; and (3) all opinions expressed in this announcement have beenarrived at after due and careful consideration and are found on bases and assumptions that are fair and reasonable. 綜合損益及其他全面收益表CONSOLIDATED STATEMENT OF PROFIT OR LOSS ̃ٽᭅ̃ 綜合財務報表附註NOTES TO THE CONSOLIDATED FINANCIAL STATEMENTS 1. GENERAL INFORMATION AND BASIS OF PREPARATION China Health Group Inc. (the “Company”the Company and itssubsidiaries are collectively referred to as the “Group”) wasincorporated in the Cayman Islands on 21 May 2002 as anexempted company with limited liability under the CompaniesLaw of the Cayman Islands and its shares are listed on the GEMof the Stock Exchange of Hong Kong Limited (the “StockExchange”). The address of its registered office and head officein China are P.O. Box 31119 Grand Pavilion, Hibiscus Way, 802West Bay Road, Grand Cayman, KY1 – 1205, Cayman Islandsand Building 17, Jianwai SOHO, Chaoyang District, Beijing,China respectively. The Company’ultimate controlling party isMr. GUO Xia, who is also an executive director of the Company. The consolidated financial statements are presented in Renminbi(“RMB”), which is also the functional currency of the Companyand its subsidiaries. Going concern basis TheGroupincurredanetlossofapproximatelyRMB14,519,000,000 for the year ended 31 December 2024 andas at 31 December 2024, the Group has cash and cash equivalentof approximately RMB14,194,000 but has current liabilities ofapproximately RMB31,243,000 as at 31 December 2024. Theseevents or conditions indicate a material uncertainty exists thatmay cast significant doubt about the Group’s ability to continueas going concern. The directors of the Company have taken the following measuresto mitigate the liquidity pressure and to improve the financialposition of the Group: (i)The Group is taking active steps to receive settlement ofthe trade receivables from related companies, which a directorand the ultimate controlling shareholder of the Company, Mr.GUOXia,has control,amounted to approximatelyRMB48,186,000which were included in trade and billsreceivables. The related companies have agreed to settle tradereceivables of approximately RMB18,000,000 during the yearending 31 December 2025; and (ii)The Group is taking actions to control operating costsandimprove operating revenue and the directors of theCompany anticipates that the Group will generate positivecash flows from its operations in the foreseeable future. ̃
"//6"-
3&1035 ٽᭅ̃ Based on the Group’s cash flow projections, covering a period oftwelve months from the end of the reporting period prepared bythe management and taking into account of the effectiveness andfeasibility of the above measures, the directors of the Companyconsider the G